Labelling experiments
[11C]carbon monoxide. The reactor was heated at the setting
temperature (190 ЊC) for 5 min. The crude product was treated
Method A (11C-compounds 1a–1g and 2–4). Tetrakis(triphenyl-
phosphine)palladium() (≈ 2.6 µmol) and halide (≈ 9.0 µmol)
were placed in a vial (1 ml). The vial was flushed with nitrogen
gas and dry THF (250 µl) was added. The resulting mixture was
heated at 70 ЊC for 1 min and kept at room temperature for
10–15 min. Amine (≈ 50 µmol) was added and the reaction
mixture was shaken just before injection into the micro-
autoclave pre-charged with [11C]carbon monoxide. The mixture
was heated at the selected temperature for 5 min. The crude
product was transferred to a pre-evacuated vial (3 ml). The
micro-autoclave was washed with THF (250 µl) and the wash
collected in the same vial. The radioactivity of the reaction
mixture was measured before and after purging with nitrogen.
The solvent was reduced to 0.1 ml by heating at 80 ЊC
and flushing with nitrogen. The crude mixture was dissolved
in acetonitrile–water and injected onto a semi-preparative
LC. The identity of the collected fraction was determined by
analytical LC and LC-MS.
as described in method B.
Method C
1-[carbonyl-11C]Benzoyl-3-methyl-1H-indole (11). A capped
vial (1 ml) containing
a solution of tetrakis(triphenyl-
phosphine)palladium() (3.0 mg, 2.6 µmol) and iodobenzene
(12b) (1.0 µl, 8.9 µmol) in dry THF (125 µl) was flushed with
nitrogen and shaken for 10 min. The reaction mixture was
injected into the micro-autoclave pre-charged with [11C]carbon
monoxide. The micro-autoclave was heated at 100 ЊC for
4 minutes. The crude product was placed in a pre-evacuated
vial (3 ml), which was charged with 3-methyl-1H-indole (25)
(5.9 mg, 45 µmol) dissolved in THF (75 µl), treated with BuLi
(1.6 M in hexane, 15 µl) followed with trimethyltin chloride
(1 M in THF, 25 µl), heated at 70 ЊC for 1 min and kept at room
temperature for 15 min. The resulting mixture was heated at
80 ЊC for an additional 6 min, and the remaining procedure was
as described in method B.
7-Pyridin-2-yl-7-azabicyclo[4.2.0]octa-1,3,5-trien-8-[carb-
onyl-11C]one (7). N-(2-Bromophenyl)pyridin-2-amine (17) (4.4
mg, 18 µmol) and tetrakis(triphenylphosphine)palladium()
(3.0 mg, 2.6 µmol) were used as described in method A.
Acknowledgements
We thank Professor Wyn Brown for linguistic advice and the
Science Council for grant K3464 (B. L.).
Method B (11C-compounds 5–6 and 8–10b). A capped vial
(1 ml) containing a solution of tetrakis(triphenylphosphine)-
palladium() (≈ 2.6 µmol) and halide (≈ 9.0 µmol) in dry THF
(125 µl) was flushed with nitrogen. The reaction mixture was
heated at 70 ЊC for 1 min and kept at room temperature for
10–15 min. Another capped vial (1 ml) was flushed with nitro-
gen and charged with amine (≈ 25.0 µmol) in anhydrous
THF (100 µl) and lithium bis(trimethylsilyl)amide (1 M in
THF, 25 µl, 25 µmol), then shaken and kept at room temper-
ature for 10–15 min. The reaction mixture in the first vial was
transferred to the vial containing the amine just before injection
into the micro-autoclave pre-charged with [11C]carbon mon-
oxide. The micro-autoclave was heated at 150 ЊC for 5 minutes.
The crude product was transferred to a vial (3 ml) under
reduced pressure. The crude product was treated as described
for method A.
References
1 (a) H. N. Wagner, Z. Szabo, J. W. Buchanan, Principles of
Nuclear Medicine, W. B. Saunders Company, Philadelphia, 1995;
(b) B. Långström, T. Kihlberg, M. Bergström, G. Antoni,
M. Björkman, B. H. Forngren, T. Forngren, P. Hartvig,
K. Markides, U. Yngve and M. Ögren, Acta. Chem. Scand., 1999,
53, 651–669.
2 (a) M. R. Kilbourn, P. A. Jarabek and M. J. Welch, J. Chem. Soc.,
Chem. Commun., 1983, 861–862; (b) S. K. Zeisler, M. Nader,
A. Theobald and F. Oberdorfer, Appl. Radiat. Isot., 1997, 48, 1091–
1095.
3 H. M. Colquhoun, D. J. Thompson and M. V. Twigg, Carbonylation,
Plenum Press, New York, 1991.
4 T. Kihlberg and B. Långström, Method and apparatus for produc-
tion and use of [11C]carbon monoxide in labeling synthesis.,
Swedish Patent Application, submitted.
5 (a) T. Kihlberg and B. Långström, J. Org. Chem., 1999, 64, 9201–
9205; (b) F. Karimi, T. Kihlberg and B. Långström, J. Chem. Soc.,
Perkin Trans. 1, 2001, 1528–1531; (c) F. Karimi and B. Långström,
J. Chem. Soc., Perkin Trans. 1, 2002, 2111–2116; (d ) F. Karimi
and B. Långström, J. Chem. Soc.,Perkin Trans. 1, 2002, 2256–2259;
(e) T. Kihlberg, F. Karimi and B. Långström, J. Org. Chem., 2002,
67, 3687–3692.
6 (a) Y. Andersson and B. Långström, J. Chem. Soc., Perkin. Trans. 1,
1995, 287–289; (b) P. Lidström, T. Kihlberg and B. Långström,
J. Chem. Soc., Perkin Trans. 1, 1997, 2701–2706; (c) T. Kihlberg and
B. Långström, J. Org. Chem., 1999, 64, 9201–9205; (d ) T. Kihlberg,
F. Karimi and B. Långström, J. Label. Compd. Radiopharm., 1999,
42(suppl. 1), 86–88; (e) F. Karimi, T. Kihlberg and B. Långström,
J. Chem. Soc., Perkin Trans. 1, 2001, 1528–1531.
7 T. Khilberg, G. Antoni, M. Björkman, F. Karimi, O. Rahman,
M. Ögren and B. Långström, Synthesis and application of
isotopically compounds, eds. U. Pleiss and R. Voges, Wiley, Dresden,
Germany, 2000, pp. 322–325.
8 J. K. Stille, Angew. Chem., Int. Ed. Engl., 1986, 25, 508–524.
9 O. Rahman, T. Kihlberg, B. Långström, J. Chem. Soc., Perkin Trans.
1, 2002, in press.
10 P. Lidström, T. Kihlberg and B. Långström, J. Chem. Soc.,
Perkin Trans. 1, 1997, 2701–2706.
11 D. R. Christman, R. D. Finn, K. I. Kalstrom and A. P. Wolf,
Int. J. Appl. Radiat. Isot., 1975, 26, 435–442.
12 T. Kihlberg, P. Bjurling and B. Langström, J. Label. Compd.
Radiopharm., 1995, 37, 675–676.
13 T. Kihlberg, P. Lidström and B. Långström, Abstract from XIIth
International Symposium on Radiopharmaceutical Chemistry,
Uppsala, Sweden, Wiley, 1997, pp. 781–782.
7-Pyridin-2-yl-7-azabicyclo[4.2.0]octa-1,3,5-trien-8-[carb-
onyl-11C]one (7). A vial (1 ml) was charged with tetrakis-
(triphenylphosphine)palladium() (3.0 mg, 2.6 µmol), N-(2-
bromophenyl)pyridin-2-amine (17) (4.2 mg, 17 µmol) and THF
(225 µl). The solution was heated at 70 ЊC for 1 min and kept at
room temperature for 10–15 min. Lithium bis(trimethylsilyl)-
amide (1 M in THF, 25 µl, 25 µmol) was added just before
injection into the micro-autoclave. The resulting mixture was
treated as described for method B.
N-Phenyl[carbonyl-11C]benzamide (9a) using the correspond-
ing triflate. Tetrakis(triphenylphosphine)palladium() (3.0 mg,
2.6 µmol) and phenyl trifluoromethanesulfonate (1.4 µl, 8.9
µmol) were put into a vial (1 ml). The vial was flushed with
nitrogen gas and dry THF (100 µl) was added. The resulting
mixture was heated at 70 ЊC for 1 min and kept at room temper-
ature for 5 min. The resulting mixture was transferred into
another vial (1 ml) containing a solution of tetrabutyl-
ammonium iodide (18 mg, 49 µmol) in DMSO (25 µl). The
reaction mixture was flushed with nitrogen gas, heated at 70 ЊC
for 1 min and kept at room temperature for 15 min. Another
capped vial (1 ml) was flushed with nitrogen and charged with
amine in anhydrous THF (100 µl) and lithium bis(trimethyl-
silyl)amide (1 M in THF, 25 µl, 25 µmol), then shaken and kept
at room temperature for 10–15 min. The reaction mixture in the
first vial was transferred to the vial containing the amine just
before injection into the micro-autoclave pre-charged with
14 P. Lidström, T. Kihlberg and B. Långström, J. Chem. Soc.,
Perkin Trans. 1, 1997, 2701–2706.
O r g . B i o m o l . C h e m . , 2 0 0 3 , 1, 5 4 1 – 5 4 6
545